MMP expression and abnormal lung permeability are important determinants of outcome in IPF

European Respiratory Journal

Volumn 33, Issue 1, 2009, Pages 77-84

  McKeown, S ^a   Richter, A G ^b   O'Kane, C ^a   McAuley, D F ^a   Thickett, D R ^b,c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c 1st Floor Nuffield House ^*  (United Kingdom)

Author keywords

Idiopathic pulmonary fibrosis; Matrix metalloproteinase; Vascular endothelial growth factor

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PREDNISOLONE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CAPILLARY PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; HUMAN CELL; INFLAMMATION; LUNG ALVEOLUS CELL; LUNG FUNCTION; LUNG LAVAGE; MALE; PARAMETER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PERMEABILITY INDEX; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION;

ADULT; AGED; AGED, 80 AND OVER; BRONCHOALVEOLAR LAVAGE; CAPILLARY PERMEABILITY; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MATRIX METALLOPROTEINASES, SECRETED; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58849094483     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00060708     Document Type: Article

References (25)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
2. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151.
3. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE Jr. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133: 226-232.
4. Günther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83: 853-860.
5. Cosgrove GP, Brown KK, Schiemann WP, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004; 170: 242-251.
6. Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 2001; 56: 916-923.
7. Keane MP, Arenberg DA, Lynch JP 3rd, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159: 1437-1443.
8. Henry MT, McMahon K, Mackarel AJ, et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J 2002; 20: 1220-1227.
9. Pardo A, Gibson K, Cisneros J, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005; 2: e251.
10. Vuorinen K, Myallärniemi M, Lammi L, et al. Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases. Apmis 2007; 115: 969-975.
11. Thickett DR, Armstrong L, Christie SJ, Millar AB. Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164: 1601-1605.
12. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-κB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007; 67: 3310-3319.
13. Jin HY, Lee KS, Jin SM, Lee YC. Vascular endothelial growth factor correlates with matrix metalloproteinase-9 in the pleural effusion. Respir Med 2004; 98: 115-122.
14. Thickett DR, Armstrong L, Millar AB. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med 2002; 166: 1332-1337.
15. Perkins GD, Chatterjie S, McAuley DF, Gao F, Thickett DR. Role of nonbronchoscopic lavage for investigating alveolar inflammation and permeability in acute respiratory distress syndrome. Crit Care Med 2006; 34: 57-64.
16. Elkington PT, Green JA, Emerson JE, et al. Synergistic upregulation of epithelial cell matrix metalloproteinase-9 secretion in tuberculosis. Am J Respir Cell Mol Biol 2007; 37: 431-437.
17. Tang W, Guo Q, Qu X, et al. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma. Oncol Rep 2007; 17: 737-741.
18. Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllärniemi M. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res 2007; 33: 357-373.
19. Suga M, Iyonaga K, Okamoto T, et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000; 162: 1949-1956.
20. Matute-Bello G, Wurfel MM, Lee JS, et al. Essential role of MMP-12 in Fas-induced lung fibrosis. Am J Respir Cell Mol Biol 2007; 37: 210-221.
21. Kanazawa H, Tochino Y, Asai K. Angiopoietin-2 as a contributing factor of exercise-induced bronchoconstriction in asthmatic patients receiving inhaled corticosteroid therapy. J Allergy Clin Immunol 2008; 121: 390-395.
22. Roberts JR, Perkins GD, Fujisawa T, et al. Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit Care Med 2007; 35: 2164-2170.
23. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 2006; 290: L209-L221.
24. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
25. Lemjabbar H, Gosset P, Lechapt-Zalcman, et al. Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. Am J Respir Cell Mol Biol 1999; 20: 903-913.